T Subramaniam1, P Lennon, J P O'Neill. 1. Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland, tksorl@outlook.com.
Abstract
BACKGROUND: Adenoid cystic carcinoma is a malignant tumour of major and minor salivary glands. Distant metastasis and poor survival are persistent in the literature, with recent publications aimed at understanding molecular pathogenesis and development of pharmaceutical therapeutic options. AIM: Provide an update of recent studies in the management of adenoid cystic carcinoma of the head and neck. METHODS: Literature search using Medline, Scopus, Google Scholar, the Cochrane Database of Systematic Reviews and the Cochrane central register of controlled trials for articles on adenoid cystic carcinoma from January 2005 to January 2015. CONCLUSION: Adenoid cystic carcinoma is characterized by a slow growing mass, with distant metastasis independent of local or regional control. Primary tumour resection remains the preferred option with radiotherapy having an adjuvant role. Recent advances have been made with novel targeted therapies however, limited to clinical trials and advanced disease.
BACKGROUND:Adenoid cystic carcinoma is a malignant tumour of major and minor salivary glands. Distant metastasis and poor survival are persistent in the literature, with recent publications aimed at understanding molecular pathogenesis and development of pharmaceutical therapeutic options. AIM: Provide an update of recent studies in the management of adenoid cystic carcinoma of the head and neck. METHODS: Literature search using Medline, Scopus, Google Scholar, the Cochrane Database of Systematic Reviews and the Cochrane central register of controlled trials for articles on adenoid cystic carcinoma from January 2005 to January 2015. CONCLUSION:Adenoid cystic carcinoma is characterized by a slow growing mass, with distant metastasis independent of local or regional control. Primary tumour resection remains the preferred option with radiotherapy having an adjuvant role. Recent advances have been made with novel targeted therapies however, limited to clinical trials and advanced disease.
Authors: Christopher L Ellington; Michael Goodman; Scott A Kono; William Grist; Trad Wadsworth; Amy Y Chen; Taofeek Owonikoko; Suresh Ramalingam; Dong M Shin; Fadlo R Khuri; Jonathan J Beitler; Nabil F Saba Journal: Cancer Date: 2012-01-31 Impact factor: 6.860
Authors: Stijn van Weert; Isaäc van der Waal; Birgit I Witte; C René Leemans; Elisabeth Bloemena Journal: Oral Oncol Date: 2014-10-28 Impact factor: 5.337
Authors: Sarah Atallah; Morgane Marc; Antoine Schernberg; Florence Huguet; Isabelle Wagner; Antti Mäkitie; Bertrand Baujat Journal: Cancer Manag Res Date: 2022-06-04 Impact factor: 3.602
Authors: João Augusto Vianna Goulart-Filho; Victor Angelo Martins Montalli; Fabrício Passador-Santos; Ney Soares de Araújo; Vera Cavalcanti de Araújo Journal: Diagn Pathol Date: 2019-02-08 Impact factor: 2.644